http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201414489-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6660ac658bf2d152a3ab472758aad8a0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
| filingDate | 2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_498218dd64ecf9d6d63335b762b251e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98f4d44c8fd9b252d743d7321d310b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90180c4bfcd3480220da18c9e6204eec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08aba90abbe9f57652d864807d50f1dc |
| publicationDate | 2014-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201414489-A |
| titleOfInvention | Medicinal composition containing heme-based oxygen carrier for cancer target treatment and prevention of cancer recurrence |
| abstract | The present invention provides a pharmaceutical composition containing a heme-based oxygen carrier for treating cancer, preventing cancer tumor recurrence and metastasis. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, bortezomib, doxorubicin, cisplatin or any combination thereof. The heme-based oxygen carrier in the composition is capable of targeting surface receptors expressed on cancer cells and promoting a heme-based oxygen carrier via the receptor-mediated mechanism and the chemotherapeutic agent is taken up by the cancer cells. The heme-based oxygen carrier inhibits the performance of hypoxic response elements such as HIF1 alpha, VEGF, ET1, VHL, and the like. The pharmaceutical composition of the present invention is also suitable for inducing apoptosis or cell death of a cell called self-renewal of a cancer stem cell and a tumor-initiated cell which is localized in hypoxic sputum of a cancerous tumor. |
| priorityDate | 2012-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1129.